Related Experiment Videos
Mumps incidence in Israel--impact of MMR vaccine
P E Slater1, M Roitman, C Costin
1Department of Epidemiology, Ministry of Health, Jerusalem, Israel.
Background:
Measles-mumps-rubella (MMR) vaccine replaced measles vaccine in the routine childhood vaccination schedule in Israel in December 1988, primarily to eliminate congenital rubella syndrome. In this observational study, we report on changes in mumps incidence in Israel from the time of the introduction of MMR vaccine until the end of 1991.
Methods:
The report is based upon passive surveillance of mumps incidence, which has been notifiable in Israel since 1977.
Results:
In the three years since the introduction of MMR vaccine, reported mumps incidence has fallen to less than 10% of the pre-vaccine period.
Conclusions:
Although this report is based on a relatively short period of observation, it can be tentatively concluded that MMR has led to a reduction in mumps incidence in Israel. It would be imprudent, however, to predict that mumps outbreaks will not occur in the future, and further observation of morbidity data will be needed to determine the magnitude and durability of the observed trend.
Insights
The Measles-mumps-rubella (MMR) vaccine significantly reduced mumps incidence in Israel, falling to less than 10% of pre-vaccine levels. Continued monitoring is needed to confirm the long-term impact of MMR vaccination on mumps outbreaks.
Area of Science:
- Public Health
- Vaccinology
- Epidemiology
Background:
- The Measles-mumps-rubella (MMR) vaccine was introduced into Israel's routine childhood immunization program in December 1988.
- The primary objective for introducing the MMR vaccine was to eradicate congenital rubella syndrome.
Purpose of the Study:
- To assess the impact of the MMR vaccine on mumps incidence in Israel.
- To observe changes in mumps occurrence following the vaccine's introduction.
Main Methods:
- The study utilized passive surveillance data for mumps.
- Mumps incidence data was collected from 1977 onwards, as it is a notifiable disease in Israel.
Main Results:
- Reported mumps incidence decreased to below 10% of the pre-vaccine period within three years of MMR vaccine introduction.
- A substantial decline in mumps cases was observed post-MMR implementation.
Conclusions:
- The MMR vaccine appears to have effectively reduced mumps incidence in Israel.
- Further long-term surveillance is necessary to determine the full impact and durability of this reduction.